Producer: JSC Pharmak Ukraine
Code of automatic telephone exchange: S01XA21
Release form: Liquid dosage forms. Drops are eye.
General characteristics. Structure:
Active ingredient: taurine;
1 ml of drops contains taurine 40 mg;
excipients: methylparahydroxybenzoate (Е 218), water for injections.
Pharmacodynamics. Taufon treats drugs of amino acids which stimulate reparative and regeneration processes at diseases of a retina of an eye of dystrophic character, traumatic damages of an eye, pathological processes which are followed by sharp disturbance of metabolism of these fabrics. As the connection containing sulfur drug contributes to normalization of functions of cellular membranes, optimization of power and exchange processes, maintenance of constancy of electrolytic composition of cytoplasm of cells, braking of synoptic transfer (a neuromediator role).
Pharmacokinetics. At an instillation Taufon gets into eye tissues where has the specific effect. At use in therapeutic doses drug is practically not soaked up in a system blood stream.
Main physical and chemical properties: transparent colourless liquid.
Indications to use:
Dystrophic defeats of a cornea and retina of an eye, including hereditary tapetoretinalny degenerations; senile, diabetic, traumatic and beam cataracts; as cure of stimulation of reparative processes for cornea injuries; as an additional tool at treatment of an open angle glaucoma.
Route of administration and doses:
Taufon appoint the adult.
For treatment of a cataract appoint 2-3 drops 2-4 times a day. A course of treatment – 3 months. To repeat a course at an interval of 1 month.
At injuries to apply 2-3 drops 2-4 times a day for 1 month.
For treatment of a tapetoretinalny degeneration and other dystrophic diseases of a retina, the getting cornea injuries the drug is administered under a conjunctiva on 0,3 ml 4% of solution for 10 days once a day. To repeat a course of treatment in 6-8 months.
At an open angle glaucoma Taufon dig in 2-3 drops in a conjunctival sac 2 times a day in 20-30 minutes prior to use of Timololum. The course of treatment is defined individually.
Features of use:
At an open angle glaucoma drug is used in combination with Timololum in 20-30 minutes prior to Timololum instillation.
Ability to influence speed of response at control of motor transport or work with other mechanisms.
It was not studied.
Drug, as a rule, is well transferred. At certain patients development of allergic reactions, a hyperemia of a conjunctiva, an itch, burning and gripes in eyes is possible.
Interaction with other medicines:
At combined use with eye drops of Timololum potentsiirovanny decrease in intraocular and arterial pressure is observed.
Hypersensitivity to drug components.
Cases of overdose are not described.
Use during pregnancy or feeding by a breast.
Efficiency and safety of use during pregnancy or feeding by a breast were not investigated.
Efficiency and safety of use to children were not investigated.
Period of validity. 3 years. Not to use drug after the termination of the period of validity specified on packaging. To store in the place protected from light at a temperature from 8 °C to 15 °C. To store in the place, unavailable to children.
According to the recipe
On 5 ml or 10 ml in a bottle. On 1 bottle in a pack.